Journal
JCO ONCOLOGY PRACTICE
Volume 16, Issue 11, Pages 733-+Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/OP.20.00113
Keywords
-
Categories
Ask authors/readers for more resources
Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) were first recognized as a distinct entity in 2001, 5 years after the approval of the first aromatase inhibitor, anastrozole. Musculoskeletal symptoms can severely affect patients' quality of life and also lead to premature discontinuation of aromatase inhibitor therapy. Several interventions for managing AIMSS have been investigated in the last decade, with some demonstrating promise. This article provides an evidence-based summary to guide practicing oncologists in regard to the epidemiology, prevention, and treatment of AIMSS. (C) 2020 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available